Patients with gout refractory to standard treatment receiving SEL-212 in either low dose (LD; 0.1 mg/kg) or high dose (HD; 0.15 mg/kg) formulations showed improvements in health-related quality of life (HRQoL) and tender joint count, according to data presented at the 2024 European Congress of Rheumatology (EULAR). A decline in urate over time was observed based on the similar rates of gout flare during the first 3 months of treatment and subsequent reductions in frequency of flare at the end of the trial.

Hyperuricemia, defined as serum uric acid (sUA) levels of ≥ 6.8 mg/dL, can lead to the accumulation of monosodium urate crystals in the cartilage, soft tissue, and joints, and may result in the formation of tophi, tender and swollen joints, gout flares, and diminished HRQoL.

Source: MDMag

To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

https://www.hcplive.com/view/novel-sel-212-therapy-improves-quality-of-life-in-patients-with-gout